Ligand Pharmaceuticals | LGND - Net Income


Ligand Pharmaceuticals reported $48.51M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Agenus USD 39.17M 49.8M Mar/2026
Amgen USD 2.38B 556M Jun/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
Baxter International USD 126M 141M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Enviri Corporation USD -84.28M 61.97M Dec/2025
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Pacira USD 4.65M 1.74M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Veracyte USD 25.49M 3.22M Jun/2026